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Abstract
Purpose Long-term breast cancer survivors are women surviving at least 5 years after diagnosis. This systematic review aimed to
summarize the main characteristics and patterns of healthcare service use (frequency of visits, health providers visited, and
preventive care performed) among long-term breast cancer survivors.
Methods We used standard Cochrane Collaboration methods and searched the MEDLINE and EMBASE databases up to
January 2018. We included English language observational studies reporting health service use among long-term cancer survi-
vors. The quality of the studies was appraised through the ROBINS-I assessment tool. Two independent reviewers performed
both the study quality assessment and the data extraction.
Results A total of 23 observational studies were included that reported data on health services use by long-term breast cancer
survivors. Despite heterogeneity among studies, about half of them reported that breast cancer survivors visited a medical
provider at least once a year, as recommended by breast cancer survival guidelines. Although survivors visited medical providers
with the recommended frequency, a substantial number used specialist care instead of primary care during follow-up. The results
showed underuse of the recommended annual mammogram.
Conclusions Long-term breast cancer survivors differ in their health services use with regard to the frequency of visits as well as
the health providers seen. Our results indicate the need for active surveillance through primary care providers in coordinationwith
specialized care.
Implications for cancer survivors This review could help to standardize the management of breast cancer survivors and decision-
makers to adapt their guidelines and clinical protocols.
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Introduction
Long-term breast cancer survivors are those women who sur-
vive free from cancer recurrence or new primary cancer for at
least 5 years [1]. It is well-known that survival has increased in
women with breast cancer, particularly in European countries
as well as in the USA, and trends suggest that it will keep
increasing. Recent data from the NORDCAN Project show that
around 87% of women diagnosed with breast cancer in the
Nordic countries will live disease-free for at least 5 years and
74–83% for at least 10 years [2], which is slightly higher than in
the rest of Europe. In the USA, the 5-year relative survival rate
for all types of breast cancer was 90% in 2014 [3].
In 2011, the survival rate for breast cancer ranked fifth for all
cancers and third when analyzing only women [4]. The in-
creased likelihood of survival can be explained by numerous
factors, such as improvements in breast cancer screening and
advances in diagnosis and treatment and aging [5, 6]. Due to the
increase in survivorship rates and life expectancy among breast
cancer survivors, the pool of long-term breast cancer survivors
is likely to expand considerably in the coming decades [7–10].
Cancer survivors’ follow-up is an essential phase of cancer
care and includes surveillance, symptom control interven-
tions, comorbidities, and complications treatment, as well as
psychosocial needs and care coordinationmechanisms. This is
usually performed by both the primary care providers (GP,
nurses, social workers) and the specialized attention (medical
oncologist, radiation oncologist, gynecologists, physiothera-
pist, psychologist) [8, 11, 12].
The critical point in survival care appears after the discharge
from oncology or specialist care, when these women remain at
long-term risk of complications due to treatment and the risk of
relapses [13]. However, it is not clear whether women who have
received cancer therapy are more likely to develop other comor-
bidities than those without a history of cancer [14]. Because of
this, it is essential that breast cancer survivors, besides breast
cancer specific prevention, receive the standardized preventive
care as the women without cancer history. Furthermore, clear
guidelines are needed to assist decision-making on health care
planning and follow-up in this group of women and to improve
the efficiency of primary care officers [1].
The National Cancer Institute from USA sets among their
six priorities, for cancer-related public health research, to
study how to meet the needs and challenges of a growing
population of cancer survivors [15]. It is essential to provide
evidence on how health systems should answer to the long-
term survivors’ follow-up. The use of healthcare services by
breast cancer survivors presents new challenges for health
organizations in terms of the role of every health professional
and the characteristics and frequency of visits and tests per-
formed. While there are many evidence-based guidelines for
diagnosis and treatment, there are far fewer for long-term sur-
vivorship follow-up [16–18] and, particularly, there is little
evidence on the type of follow-up and health needs of this
population group [17–23]. Evidence synthesis methods are
an excellent alternative for decision-makers to assess the
scope, quality, and relevance of available data and to identify
areas of clinical uncertainty and gaps in available scientific
information.
This systematic review aimed to describe the main charac-
teristics and patterns of healthcare services use (frequency of
visits, health providers visited, and preventive care performed)
among long-term breast cancer survivors.
Methods
Study design and search strategy
This systematic review was conducted following standard
Cochrane Collaboration methods [24] with a predetermined
review protocol registered in the PROSPERO database
(CRD42018089309). We searched MEDLINE and EMBASE
databases from their inception to 24 January 2018, following
the PRISMA statement [25], to obtain all the existing literature
on health services use and preventive care in long-term breast
cancer survivors. Health services use was assessed through the
frequency of visits to primary care providers, specialists and
other health professionals, and the main reason to visit.
Preventive care included all tests performed in women de-
signed to identify a new incident cancer or relapse and all the
surveillance tests for cancer-related reasons or not.
The search strategy included a combination of controlled
vocabulary and search terms related to long-term breast cancer
survivors and health services use, such as breast cancer, cancer
survivor, survivorship, health services use, health care
utilization, general practitioner, specialist, and follow-up care.
The search strategy can be found in Appendix A. Stage I
screening identified titles and abstracts related to the main ob-
jective and was done by two independent reviewers. Stage 2
screened the full-text articles against the inclusion and exclu-
sion criteria, described below. Articles meeting the inclusion
criteria were included in the synthesis; this phase was also
conducted by two reviewers. In all cases, agreement was
reached after discussion of any differences. The results of this
process are reported in a PRISMA flowchart (Fig. 1).
Inclusion and exclusion criteria
Inclusion was limited to observational studies written in
English. Systematic reviews were used as the source of pri-
mary studies. The included studies were published between
2006 and January 2018. Studies reporting the frequency of
health care use in long-term breast cancer survivors, defined
as the period starting 5 years after diagnosis, were included.
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We excluded narrative reviews, conference abstracts, rec-
ommendations, summary reports, and editorials. Studies not
providing detailed information by survival period (at least
5 years after diagnosis) were excluded, as were studies about
cancer in general that did not provide results for breast cancer
specifically. Studies published before 2005 were excluded, as
the treatment for breast cancer changed then because of the
introduction of trastuzumab therapy. Treatment with this
trastuzumab in HER2-positive tumors at an early stage im-
proved overall survival and disease-free survival [26]. Lastly,
studies aiming to analyze patients’ and health care providers’
satisfactions with healthcare were also excluded unless they
reported data on health services use.
Quality assessment and data extraction
We developed a predefined form to extract information from
included studies. The following information was selected: au-
thor, country, year of publication, study design, purpose, pop-
ulation characteristics, survival period, type of analysis, re-
sults by outcomes (health services use and preventive care),
data source, and study limitations. Two reviewers indepen-
dently extracted the data for the included studies.
Disagreements between them were resolved by consensus.
To assess the methodological quality of the studies, we used
the Risk of Bias in Non-randomized Studies of Interventions
(ROBINS-I) assessment tool [27]. The following sources of bias
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Fig. 1 PRISMA flowchart
illustrating study inclusion
J Cancer Surviv
were assessed: (i) bias due to confounding, (ii) bias in the selec-
tion of participants into the study, (iii) bias due to missing data,
(iv) bias in measurement of outcomes, (v) bias in the selection of
the reported result, and (vi) overall bias. For each study, the risk
of bias for each domain was rated as low risk of bias, moderate
risk of bias, serious risk of bias, critical risk of bias, or no
information. The final risk of bias assessment was based on
consensus by two reviewers following the ROBINS guidelines
[27] and was considered in the interpretation of the results.
Analysis and synthesis of the results
There was wide heterogeneity across study populations and di-
versity in the categories of survivor follow-up among the studies.
This and the way the results were analyzed and presented in the
studies precluded the possibility of pooling the data across stud-
ies. Therefore, we performed a narrative synthesiswith tabulation
of the characteristics and main outcomes of the included studies.
The studies are ordered according to study design in the tables as
follows: retrospective cohort with a control group, retrospective
cohort without a control group, and cross-sectional studies.
Results
A total of 1089 abstracts were eligible for title and abstract
screening, and 61 were checked at the full-text reading.
Twenty-three observational studies met the eligibility criteria
and were included in the final review. Of them, 12 (52.2%) were
retrospective cohort studies without a control group, 6 (26.1%)
were retrospective cohort studies with a control group, and 5
(21.7%) were cross-sectional studies. The publication period
ranged from 2005 to 2018, and 9 studies (39%) were conducted
in theUSA, 11 (48%) in Europe, ofwhich 3 (13%)were from the
UK. The data sourcewas tumor registries or hospital databases in
12 (52.2%) of the included studies, self-reported surveys or in-
terviews in 9 (39.1%) studies, and 2 (8.7%) used both sources.
Population characteristics
The 23 studies involved 476,127 women aged 18 years or older
with different parameters (Table 2). The period of breast cancer
diagnosis varied from 1989 [34, 47] to 2013 [44, 46]. In terms of
location, eight studies (34.8%) included populations from both
urban and rural areas, and 3 (13%) included only urban areas,
while 12 (52.2%) did not report characteristics regarding loca-
tion. To assess comorbidities during follow-up, 4 (17.4%) of the
23 articles used the Charlson comorbidity index, 6 (26.1%) did
not report information about comorbidities, and the rest included
a list of different diseases associated with breast cancer treat-
ment. More details on comorbidities are shown in Table 1.
The range of reported survival periods differed among all
the studies, even though all of them included survival of at
least 5 years or more. Lu et al. [39] included the longest
follow-up period (16 years from diagnosis), followed by the
studies by Maddams et al. [40] and Weaver et al. [49] with 16
and 14 years of follow-up, respectively.
Outcomes
To summarize the outcomes, we performed a tabulation of the
given measures and risk estimators (Table 2). A total of 10
(44%) studies described both healthcare use and preventive
care, 9 (39%) described healthcare utilization, and 4 (17%)
described preventive health practices. No differences were
found in terms of reported outcomes by country.
Health services use
Eleven studies reported that breast cancer survivors visited a
primary care provider or a specialist at least once a year [28,
32, 33, 35, 37–39, 41, 44, 46, 50]. Some studies reported more
visits to specialist care, such as an oncologist, surgeon, radiother-
apist, gynecologist, or other specialist [28, 32, 49], while another
three studies reported more visits to primary care physicians than
to specialist care [35, 37, 38]. No differenceswere found between
the studies reporting more visits to specialized attention com-
pared to those reportingmore to primary care in terms of country,
publication period, years of follow-up, period of diagnosis, or
data source. Another study reported that 58.8% of the patients
used complementary therapies after treatment completion [32].
Regarding the reason for consultation, two studies agreed
that the main reason for breast cancer survivors visiting the
health services was non-cancer-related issues and that the med-
ical provider most frequently consulted for these health prob-
lems was the primary care provider [32, 42]. In four studies, the
predictors of health services use were lower well-being score,
having had a mastectomy, having two or more comorbidities,
having a painful arm, and younger age [34, 39, 43, 48]. Even
so, only two of these studies analyzed both primary care and
specialized attention [43, 48] and attributed the highest use to
comorbidities management in younger survivors. In contrast,
one study showed that the oldest survivors (> 70 years) had
twice the probability of visiting a physician in the last 3 months
rather than their younger counterparts. Nevertheless, that study
did not adjust by comorbidities and was focused only in the
specialized attention without taking into account the use of
health services related with age and preventive care [44].
In terms of the trends in long-term use, three studies
showed that the average number of visits decreased over time
[29, 35, 49], but other studies did not find similar results [42]
or found that this decrease occurred only in specialist care but
not in primary care physician visits [30]. However, only two
studies included age-adjusted models [30, 49].
Five studies compared health services use between survi-
vors and the general population. The likelihood of using the
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health services in breast cancer survivors compared to the
general population ranged from 1.1 (95% CI 1.09–1.12) [37]
to 1.48 (95% CI 1.34–1.64) [47]. Two studies agreed that this
increase occurred only in specialist care [31, 36] and in the use
of complementary therapies [41]. The percentages of breast
cancer survivors using complementary therapies was 26% in
10-year survivors and 13% in their matched controls [48].
Preventive care
Mammograms were the most widely studied preventive activ-
ity in this population. Mixed results were found in its utiliza-
tion. Two study showed that mammography screening was
performed according to the guidelines in breast cancer survi-
vors (once a year from the fifth year of survivorship) [28, 31],
while other four studies found underutilization regarding the
annual mammography screening recommended for breast
cancer survivors [35, 39, 43, 45]. Two studies reported that
screening mammography was more likely to be performed in
breast cancer survivors than in controls. It should be noticed
that recommendations for the two populations differ [31, 43].
The main predictor for mammography use was visits to the
health services [28, 43, 45]. Specifically, mammography is
more frequently recommended by oncologists rather than by
primary care providers or other health specialists [28, 43].
Being older with high levels of comorbidities was associated
with a lower probability of undergoing mammography [30,
31, 33, 35, 47].
Five studies [30, 38, 43, 46] evaluated imaging scans.More
imaging tests were reported in breast cancer survivors rather
than in the general population, specifically bone density scans
[31, 36, 38]. In addition, those women whose main medical
provider was an oncologist were more likely to undergo addi-
tional imaging scans [43].
In terms of general preventive activities, breast cancer sur-
vivors were more likely to receive appropriate preventive
screening than controls for both cancer and non-cancer screen-
ing [31, 38, 49]. Another study found similar results but point-
ed out that when the main medical provider was the oncolo-
gist, breast cancer survivors received additional surveillance
tests not recommended by the guidelines [28, 43, 49].
Quality assessment
Quality assessment revealed that around 90% of the included
studies showed an overall low risk of bias and only 10%were at
high risk. Specifically, four (17.4%) of studies were at high risk
of bias due to confounding. The higher risk was due to not
considering the predefined potential confounders (age at diag-
nosis, the presence of comorbidities, region, diagnostic year, and
tumor stage at diagnosis). In addition, four (17.4%) of studies
were also at high risk of bias due to outcome measurement. In
this group, three of the studies at serious risk used self-reported
information. Three studies were at high risk of bias due to par-
ticipant selection and missing data and reported results. The
quality appraisal of all the included studies is shown in Fig. 2.
Discussion
This systematic review aimed to describe the use of health
services in long-term (≥ 5 years) breast cancer survivors. A
total of 23 observational studies were included that reported
data on the health services used by women surviving at least
5 years after their breast cancer diagnosis. Despite the hetero-
geneity among studies, about half of them reported that breast
cancer survivors visit a medical provider at least once a year
but that their main medical provider was not a primary
healthcare professional, as recommended in the breast cancer
survival guidelines [16–18]. In addition, some studies sug-
gested that the number of visits to healthcare services and
interventions decreased over time. Results on preventive care
were contradictory, with some studies reporting overuse of
surveillance tests [33, 35, 43] and others underuse [31, 39,
46]. However, the studies differed in how they assessed the
frequency of the use of preventive care, hampering clear con-
clusions on the current situation in breast cancer survivors.
No previous systematic reviewswere found describing health
services use in long-term breast cancer survivors (≥ 5 years).
The review by Chopra provides useful information about pat-
terns of health care services use but was not based on long-term
survivors [51]. Like our results, those of that review showed
substantial variations in terms of the frequency, length, and in-
tensity of follow-up. The authors concluded that breast cancer
survivors report a lack of psychosocial support and information
on the comorbidities resulting from their cancer treatment.
Regarding the frequency of health services use, 10 studies
included in this systematic review [28, 33, 35, 37–39, 41, 42,
47, 50] showed results in agreement with the breast cancer
Survivorship Care Guidelines as they reported that breast can-
cer survivors visited a healthcare provider at least once a year
[16–18]. These guidelines also recommend that from the fifth
year after the completion of cancer treatment, the primary care
clinician should be the professional in charge of breast cancer
survivors’ health. We found, however, that only 6 out of 10
studies reported more visits to primary care clinicians than to
specialized care [33, 35, 37, 38, 50]. Several factors support
the idea of increasing and encouraging primary care utiliza-
tion. One is that it facilitates coordinated care and reduces
specialist visits [52]. Primary care as the axis of prevention
and health promotion activities also provides a holistic ap-
proach, guaranteeing better coverage of all the recommended
preventive activities [16–18]. Health providers in specialized
care, on the other hand, are less aware of the preventive rec-
ommendations in this population, but they still have to provide
these recommendations and receive appropriate training
J Cancer Surviv
regarding survival care. Although these 10 studies were con-
ducted in different countries, most of them were deemed to be
of moderate or high quality. Also, they reported similar re-
sults, and therefore, there is sufficient evidence to support
the recommendation of 1-year follow-up visits performed by
primary care officers.
Watson et al. [53] reported that health promotion advice
helps to mitigate the long-term effects of breast cancer,
Fig. 2 Risk of bias assessment of
included studies according to the
ROBINS-I assessment tool
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improve comorbid conditions, and potentially increase surviv-
al. In agreement with these authors, eight studies included in
this review reported similar results in breast cancer survivors
[31, 36, 38, 41, 45, 46, 48, 49]. In addition, three of them [35,
44, 49] stated that breast cancer survivors were more satisfied
when the health promotion advice was given by primary
health professionals. Overall, the available evidence indicates
that primary healthcare providers should place greater empha-
sis on post-treatment symptoms to make patients aware of
them and provide advice on their management. To do this,
the best option seems to be the shared care model since it
can facilitate a continued relationship in terms of updates
and changes in surveillance recommendations and potential
late effects [53, 54]. Primary care clinicians should consult
with the cancer treatment team to ensure evidence-based and
well-coordinated care.
Surveillance mammography has been recommended for
both the early detection of local recurrences as well as the
screening of de novo primary breast cancer [16–18]. The re-
sults of our review suggest that improvements should be made
to increase adherence to this recommendation given that
underuse of mammography has been described in four high-
quality studies [30, 35, 39, 45]. Furthermore, our results sug-
gest that clinicians should refer women for an annual mam-
mogram rather than to other screening strategies, unless the
patient is at high risk of developing de novo cancer or recur-
rence [16–18]. Heterogeneity in adherence to mammography
as a recommended surveillance test can be due to national
screening policies, professional decisions, or structural bar-
riers. Thus, efforts need to be made to ensure an annual mam-
mogram in long-term survivors and avoid losses to follow-up
[55, 56].
In terms of other preventive care, the results of two high-
quality studies included [31, 43] show that laboratory tests and
imaging scans are more frequent in breast cancer survivors
than in the general population, probably related to comorbid-
ities and surveillance of cancer recurrence surveillance.
According to expert opinion, routine laboratory or imaging
tests to evaluate breast cancer recurrence are not recommend-
ed in asymptomatic patients, while screening for other cancers
and preventive diseases should be done as in patients in the
general population [16–18]. These results support active sur-
veillance through primary care medical providers in coordina-
tion with specialized care for the correct management of co-
morbidities and to raise awareness of the appropriate prescrip-
tion of laboratory tests and imaging scans.
This review has some limitations. Some studies used self-
reported information on health services use and in the identi-
fication of breast cancer survivors [28, 29, 32, 33, 36, 41, 44,
48–50]. This could lead to a reporting bias, specifically a
memory bias, which tends to overestimate or underestimate
outcomes in survivors. Other limitations are the differences
between the populations, survival periods, age at diagnosis,
and year of diagnosis included in each study. All studies in-
cluded survivors of 5 years or more, but the periods were not
restricted at any point, so the survival periods ranged from 5 to
16 years.We could not analyze the differences between longer
and shorter survivorship, which could also help to develop
specific protocols. Survival can lead to a selection bias, since
longer survival is related to better quality of life [39, 41, 44,
49, 50] and consequently to fewer visits to health services.
Advances in breast cancer treatment need to be taken into
account, as some women included in this review did not re-
ceive the most recent therapies and might have experienced an
increased number of adverse effects or shown a different pat-
tern of health services use related to updating of survival
guidelines. Finally, we found no RCTs that tested interven-
tions in breast cancer survivors regarding the management of
long-term late effects and comorbidities due to cancer
treatment.
This is the first systematic review to include long-term
breast cancer survivors (at least 5 years of survivorship), re-
vealing heterogeneity in follow-up activities and areas for im-
provement. Further researchwithmixedmethodology is need-
ed to identify the sources of the variations, professionals’ per-
ceptions, and patients’ needs. Such knowledge would gener-
ate opportunities to mitigate current barriers to health services
and to structure shared follow-up models.
Conclusions
The literature on the use of health care services among long-
term breast cancer survivors shows substantial heterogeneity
in methods to evaluate the follow-up characteristics in this
specific population. The results of this review help to support
the need for actions to improve active surveillance through
primary care providers in coordination with specialized care
through shared care models of follow-up. Furthermore, this
approach can be strongly recommended due to the high qual-
ity of the studies in favor of the latter. Our results could also
help to standardize the appropriate management of breast can-
cer survivors and decision-makers in different contexts to
adapt their guidelines and clinical protocols. More research
is still needed to provide specific data, but this review helps
to support primary care providers as the main health providers
for this group of women with particular needs.
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